Quintiles operations in the Middle East began in May 2007 and quickly established clinical trial capabilities across Egypt, Jordan, Lebanon, Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, and Oman. Egypt is the regional office but staff are also located also in UAE (scientific office), Saudi Arabia and Lebanon.

Outstanding access to patients in the Middle East region with a population of over 200 million means that the Middle East is an important emerging region for the biopharmaceutical industry and Quintiles has a proven track record of rapid patient enrollment with high patient retention rates. Combining excellent patient recruitment with few competing studies means the region has very high potential for clinical research.